Opportunistic Screening for Cardiovascular Risk Using Chest X-Rays and Deep Learning: Associations with Coronary Artery Disease in the Project Baseline Health Study and Mass General Brigham Biobank
Abstract Body (Do not enter title and authors here): Introduction/Background: We previously demonstrated that an open-source deep learning model (CXR-CVD Risk) can predict 10-year major adverse cardiovascular events (myocardial infarction & stroke), based on a chest radiograph image (CXR). As deep learning models are black boxes, establishing the biological processes the model captures to predict risk may help build understanding and trust in the model.
Research Questions/Hypothesis: To test associations between deep-learning derived CXR-CVD Risk and markers of cardiovascular disease including coronary artery calcium (CAC) and stenosis ≥50% on CT, systolic blood pressure (SBP), ankle brachial index (ABI), and prevalent myocardial infarction and stroke.
Methods/Approach: We conducted external validation of CXR-CVD-Risk in two cohorts: 1) 2,097 volunteers in the Project Baseline Health Study (PBHS) and 2) 1,644 Mass General Brigham Biobank (MGBB) patients. The CXR-CVD-Risk model estimated 10-year cardiovascular event risk (probability between 0 and 1) from a CXR image. We calculated linear associations with SBP, ABI, and the logarithm of coronary artery calcium and odds ratios for prevalent hypertension, myocardial infarction, stroke, and, in the MGBB, coronary artery stenosis ≥50%. Analyses were adjusted for age, BMI, sex, smoking status, and enrolling site.
Results/Data: CXR-CVD-Risk was associated with CAC in both populations (PBHS: 1.11-fold increase, 95% CI: [1.07-1.16]; MGBB: 1.03-fold increase [1.01-1.05] in CAC per 1% increase in CXR-CV-Risk). CXR-CVD-Risk was also associated with SBP (0.59 mmHg increase [0.24-0.93] in SBP per 1% increase in CXR-CV-Risk), history of hypertension, history of myocardial infarction, and stroke. There was an inverse association with ABI (0.010 decrease [0.005-0.014] in ABI) in the PBHS. In the MGBB, CXR-CVD-Risk was associated with coronary artery stenosis ≥50% (OR = 1.004 [1.002-1.007]). All estimates are after covariate adjustment.
Conclusion: This deep learning CXR risk score was associated with coronary artery disease (calcium score and stenosis ≥50%), CVD risk factors, and prevalent CVD. Opportunistic screening using CXRs in the electronic record can identify patients at high risk of CVD who may benefit from prevention.
Chandra, Jay
( Harvard Medical School
, Boston
, Massachusetts
, United States
)
Lu, Michael
( Massachusetts General Hospital
, Quincy
, Massachusetts
, United States
)
Raghu, Vineet
( Massachusetts General Hospital
, Quincy
, Massachusetts
, United States
)
Karady, Julia
( Harvard University
, Boston
, Massachusetts
, United States
)
Sturniolo, Audra
( Massachusetts General Hospital
, Quincy
, Massachusetts
, United States
)
Klop-packel, Nory
( Massachusetts General Hospital
, Quincy
, Massachusetts
, United States
)
Maron, David
( Stanford University
, Stanford
, California
, United States
)
Rodriguez, Fatima
( Stanford University
, Stanford
, California
, United States
)
Mahaffey, Kenneth
( Stanford University
, Stanford
, California
, United States
)
Shah, Svati
( DUKE UNIV MEDICAL CENTER
, Hillsborough
, North Carolina
, United States
)
Author Disclosures:
Jay Chandra:DO NOT have relevant financial relationships
| Michael Lu:DO have relevant financial relationships
;
Research Funding (PI or named investigator):AstraZeneca:Past (completed)
; Research Funding (PI or named investigator):Risk Management Foundation of the Harvard Medical Institutions:Active (exists now)
; Research Funding (PI or named investigator):MedImmune:Past (completed)
; Research Funding (PI or named investigator):Kowa:Past (completed)
; Research Funding (PI or named investigator):Johnson & Johnson Innovation:Active (exists now)
; Research Funding (PI or named investigator):Ionis:Active (exists now)
| Vineet Raghu:DO NOT have relevant financial relationships
| Julia Karady:No Answer
| Audra Sturniolo:DO NOT have relevant financial relationships
| Nory Klop-Packel:No Answer
| David Maron:DO have relevant financial relationships
;
Independent Contractor:Abiomed:Active (exists now)
; Consultant:Scilex:Past (completed)
; Consultant:Regeneron:Active (exists now)
; Researcher:Cleerly, Inc:Active (exists now)
; Individual Stocks/Stock Options:Ablative Solutions:Active (exists now)
| Fatima Rodriguez:DO have relevant financial relationships
;
Consultant:HealthPals:Active (exists now)
; Consultant:iRhythm:Active (exists now)
; Consultant:HeartFlow:Active (exists now)
; Consultant:Arrowhead Pharmaceuticals:Active (exists now)
; Consultant:Edwards:Past (completed)
; Consultant:Inclusive Health:Active (exists now)
; Consultant:Kento Health:Active (exists now)
; Consultant:Movano Health:Active (exists now)
; Consultant:Esperion Therapeutics:Past (completed)
; Consultant:NovoNordisk:Active (exists now)
; Consultant:Novartis:Active (exists now)
| Kenneth Mahaffey:DO have relevant financial relationships
;
Research Funding (PI or named investigator):AHA:Active (exists now)
; Research Funding (PI or named investigator):Gilead:Past (completed)
; Consultant:Fuson:Active (exists now)
; Research Funding (PI or named investigator):Ferring:Past (completed)
; Consultant:Elsevier:Past (completed)
; Research Funding (PI or named investigator):Eidos:Active (exists now)
; Research Funding (PI or named investigator):CSL:Active (exists now)
; Consultant:CSL :Past (completed)
; Research Funding (PI or named investigator):California Institute Regenerative Medicine:Past (completed)
; Consultant:BridgeBio:Active (exists now)
; Consultant:BMS:Active (exists now)
; Consultant:Bayer:Active (exists now)
; Research Funding (PI or named investigator):Bayer:Active (exists now)
; Research Funding (PI or named investigator):Apple:Active (exists now)
; Consultant:Applied Therapuetics:Active (exists now)
| Svati Shah:DO NOT have relevant financial relationships